P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura,Mariateresa Fulciniti,Gullu Gorgun,Yu-Tzu Tai,Diana Cirstea,Loredana Santo,Yiguo Hu,Claire Fabre,Jiro Minami,Hiroto Ohguchi,Tanyel Kiziltepe,Hiroshi Ikeda,Yutaka Kawano,Maureen French,Martina Blumenthal,Victor Tam,Nathalie L. Kertesz,Uriel M. Malyankar,Mark Hokenson,Tuan Pham,Qingping Zeng,John B. Patterson,Paul G. Richardson,Nikhil C. Munshi,Nikhil C. Munshi,Kenneth C. Anderson +25 more
TL;DR: Results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.
Journal ArticleDOI
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G. Richardson,David S. Siegel,Ravi Vij,Craig C. Hofmeister,Rachid Baz,Sundar Jagannath,Christine Chen,Sagar Lonial,Andrzej Jakubowiak,Nizar J. Bahlis,Kevin W. Song,Andrew R. Belch,Noopur Raje,Chaim Shustik,Suzanne Lentzsch,Martha Q. Lacy,Joseph R. Mikhael,Jeffrey Matous,David H. Vesole,Min Chen,Mohamed H. Zaki,Christian Jacques,Zhinuan Yu,Kenneth C. Anderson +23 more
TL;DR: POM+LoDEX was effective and generally well tolerated and provides an important new treatment option for RRMM patients who have received multiple prior therapies.
Journal ArticleDOI
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani,Brendan M. Weiss,Torben Plesner,Nizar J. Bahlis,Andrew Belch,Sagar Lonial,Henk M. Lokhorst,Peter M. Voorhees,Paul G. Richardson,Ajai Chari,A. Kate Sasser,Amy Axel,Huaibao Feng,Clarissa M. Uhlar,Jianping Wang,Imran Khan,Tahamtan Ahmadi,Hareth Nahi +17 more
TL;DR: In this pooled data set, daratumumab 16 mg/kg monotherapy demonstrated rapid, deep, and durable responses, with a clinical benefit that extended to patients with stable disease or better, and no new safety signals were identified.
Journal ArticleDOI
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo,Evangelos Terpos,Cristina Nanni,Philippe Moreau,Suzanne Lentzsch,Sonja Zweegman,Jens Hillengass,Monika Engelhardt,Saad Z. Usmani,David H. Vesole,Jesús F. San-Miguel,Shaji Kumar,Paul G. Richardson,Joseph R. Mikhael,Fernando Leal da Costa,Meletios A. Dimopoulos,Chiara Zingaretti,Niels Abildgaard,Hartmut Goldschmidt,Robert Z. Orlowski,Wee Joo Chng,Hermann Einsele,Sagar Lonial,Bart Barlogie,Kenneth C. Anderson,S. Vincent Rajkumar,Brian G.M. Durie,Elena Zamagni +27 more
TL;DR: Based on the ability of 18F-FDG PET/CT to distinguish between metabolically active and inactive disease, this technique is now the preferred functional imaging modality to evaluate and to monitor the effect of therapy on myeloma-cell metabolism.
Journal ArticleDOI
The Genome Sequence of the Obligately Chemolithoautotrophic, Facultatively Anaerobic Bacterium Thiobacillus denitrificans
Harry R. Beller,Patrick S. G. Chain,Patrick S. G. Chain,Tracy E. Letain,Anu Chakicherla,Frank W. Larimer,Frank W. Larimer,Paul G. Richardson,Matthew A. Coleman,Ann P. Wood,Donovan P. Kelly +10 more
TL;DR: The genome sequence of T. denitrificans will enable elucidation of the mechanisms of aerobic and anaerobic sulfur-compound oxidation by beta-proteobacteria and will help reveal the molecular basis of this organism's role in major biogeochemical cycles and groundwater restoration.